Acorda Therapeutics

Acorda Therapeutics is a biotechnology company that focuses on the development and commercialization of therapeutics for neurological disorders, such as multiple sclerosis, stroke, and spinal cord injury. The company was founded in 1995 by Ron Cohen, Jan M. van den Bosch, and Stephen M. Harrison, and is headquartered in Ardsley, New York. Acorda Therapeutics has collaborations with Biogen, Elan Corporation, and Alkermes, and has received funding from National Institutes of Health and Michael J. Fox Foundation.

Company Overview

Acorda Therapeutics is a publicly traded company listed on the NASDAQ under the ticker symbol ACOR. The company's mission is to improve the lives of people with neurological disorders by developing and commercializing innovative therapeutics. Acorda Therapeutics has a strong focus on research and development, with a team of experienced scientists and clinicians working on the development of new treatments for neurological diseases. The company has partnerships with University of California, Los Angeles, University of Michigan, and Duke University, and has received awards from National Multiple Sclerosis Society and American Heart Association.

History

Acorda Therapeutics was founded in 1995 by Ron Cohen, Jan M. van den Bosch, and Stephen M. Harrison. The company's early focus was on the development of treatments for stroke and spinal cord injury. In 2006, Acorda Therapeutics acquired Zanaflex from Elan Corporation, and in 2009, the company launched Ampyra, a treatment for multiple sclerosis. Acorda Therapeutics has also collaborated with Biogen on the development of Vumerity, a treatment for relapsing forms of multiple sclerosis. The company has received funding from National Institutes of Health, Michael J. Fox Foundation, and Christopher and Dana Reeve Foundation.

Products and Pipeline

Acorda Therapeutics has a portfolio of products and pipeline candidates that focus on the treatment of neurological disorders. The company's lead product is Ampyra, a treatment for multiple sclerosis that improves walking in people with the disease. Acorda Therapeutics also markets Zanaflex, a muscle relaxant used to treat spasticity, and Qutenza, a topical pain relief medication. The company's pipeline includes INBRIJA, a treatment for Parkinson's disease off episodes, and CVT-301, a treatment for Parkinson's disease motor symptoms. Acorda Therapeutics has collaborations with University of California, San Francisco, University of Pennsylvania, and Columbia University.

Research and Development

Acorda Therapeutics has a strong focus on research and development, with a team of experienced scientists and clinicians working on the development of new treatments for neurological diseases. The company's research focuses on the development of small molecule and biologic therapeutics that target neurological disorders. Acorda Therapeutics has collaborations with National Institutes of Health, Michael J. Fox Foundation, and Christopher and Dana Reeve Foundation, and has received funding from these organizations to support its research. The company has also partnered with University of Oxford, University of Cambridge, and Massachusetts Institute of Technology to advance its research.

Financial Information

Acorda Therapeutics is a publicly traded company listed on the NASDAQ under the ticker symbol ACOR. The company's revenue is generated from the sales of its products, including Ampyra, Zanaflex, and Qutenza. Acorda Therapeutics has received funding from National Institutes of Health, Michael J. Fox Foundation, and Christopher and Dana Reeve Foundation to support its research and development activities. The company has also collaborated with Biogen, Elan Corporation, and Alkermes on the development and commercialization of its products. Acorda Therapeutics has received awards from National Multiple Sclerosis Society and American Heart Association for its contributions to the development of treatments for neurological disorders. Category:Biotechnology companies